KRAS-mutated Non-Small Cell Lung Cancer: Drugging the Undruggable

Area of Science:

• Oncology
• Molecular Biology
• Drug Development

Background:

• KRAS driver mutations were historically undruggable in non-small cell lung cancer (NSCLC).
• The advent of KRASG12C inhibitors targeting the inactive GDP-bound state marked a breakthrough, though initial clinical activity was modest.
• Resistance and autoimmune hepatitis complicated early KRASG12C inhibitor development.

Purpose of the Study:

• To review the evolution of KRAS inhibitors in NSCLC.
• To discuss emerging therapeutic strategies beyond KRASG12C.
• To highlight challenges and future directions in KRAS-targeted therapy.

Main Methods:

• Review of recent advancements in KRAS inhibitor development.
• Analysis of clinical data for KRASG12C inhibitors and combination therapies.
• Exploration of novel inhibitor classes targeting diverse KRAS mutations and RAS family members.

Main Results:

• Initial KRASG12C (OFF) inhibitors showed modest efficacy in KRASG12C-mutated NSCLC.
• Optimized KRASG12C inhibitors and combination therapies (e.g., with PD-1 inhibitors) are under investigation.
• New inhibitor classes, including ON-state and dual-state inhibitors, alongside panKRAS/panRAS strategies, are emerging but in early development.

Conclusions:

• The KRAS therapeutic landscape is rapidly evolving with diverse strategies.
• New inhibitors aim to broaden activity, overcome resistance, and mitigate toxicity.
• Further research is needed for novel KRAS-targeted agents to demonstrate clinical benefit.